DK0966465T3 - Inhibitorer af IMPDH-enzymer - Google Patents

Inhibitorer af IMPDH-enzymer

Info

Publication number: DK0966465T3
Authority: DK; Denmark
Prior art keywords: impdh; compounds; inhibitors; relates; inhibiting
Prior art date: 1997-03-14

Application number

DK98909165T

Other languages

Danish (da)

English (en)

Inventor

Jeffrey O Saunders

David M Armistead

Michael C Badia

Randy S Bethiel

Catharine A Frank

Doug Naegele

Perry M Novak

David A Pearlman

Steven M Ronkin

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-14

Filing date

1998-03-13

Publication date

2003-10-20

1997-03-14 Priority claimed from US08/816,764 external-priority patent/US5932600A/en

1998-03-13 Application filed by Vertex Pharma filed Critical Vertex Pharma

2003-10-20 Application granted granted Critical

2003-10-20 Publication of DK0966465T3 publication Critical patent/DK0966465T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Hematology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK98909165T 1997-03-14 1998-03-13 Inhibitorer af IMPDH-enzymer DK0966465T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/816,764 US5932600A (en)	1997-03-14	1997-03-14	Inhibitors of IMPDH enzyme
US4244397P	1997-03-28	1997-03-28
PCT/US1998/004932 WO1998040381A1 (fr)	1997-03-14	1998-03-13	Inhibiteurs de l'enzyme impdh

Publications (1)

Publication Number	Publication Date
DK0966465T3 true DK0966465T3 (da)	2003-10-20

Family

ID=26719242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98909165T DK0966465T3 (da)	1997-03-14	1998-03-13	Inhibitorer af IMPDH-enzymer

Country Status (11)

Country	Link
US (2)	US6518291B1 (fr)
EP (1)	EP0966465B1 (fr)
JP (1)	JP4327910B2 (fr)
AT (1)	ATE244717T1 (fr)
AU (1)	AU6701598A (fr)
CA (1)	CA2282398A1 (fr)
DE (1)	DE69816280T2 (fr)
DK (1)	DK0966465T3 (fr)
ES (1)	ES2201452T3 (fr)
PT (1)	PT966465E (fr)
WO (1)	WO1998040381A1 (fr)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA79749C2 (en)	1996-10-18	2007-07-25	Vertex Pharma	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
JP2002528499A (ja)	1998-10-29	2002-09-03	ブリストル−マイヤーズスクイブカンパニー	Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
WO2000026197A1 (fr)	1998-10-29	2000-05-11	Bristol-Myers Squibb Company	Nouveaux inhibiteurs de l'enzyme impdh
US6596747B2 (en)	1998-10-29	2003-07-22	Bristol-Myers Squibb Company	Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
US6420403B1 (en)	1998-10-29	2002-07-16	Edwin J. Iwanowicz	Inhibitors of IMPDH enzyme
EP1964561A1 (fr)	1999-03-19	2008-09-03	Vertex Pharmaceuticals Incorporated	Inhibiteurs d'enzyme IMPDH
DE60020556T2 (de)	1999-05-12	2005-10-27	Neurosearch A/S	Ionenkanal modulierende mittel
AU5031200A (en) *	1999-05-28	2000-12-18	Vertex Pharmaceuticals Incorporated	Method for preparing 5-substituted oxazoles
JP2001011059A (ja) *	1999-06-28	2001-01-16	Nippon Synthetic Chem Ind Co Ltd:The	５−（２−置換−４−ニトロフェニル）−オキサゾールの製造方法
JP2001011060A (ja) *	1999-06-28	2001-01-16	Nippon Synthetic Chem Ind Co Ltd:The	新規オキサゾール化合物及びその製造方法
WO2001021160A2 (fr) *	1999-09-23	2001-03-29	Axxima Pharmaceuticals Aktiengesellschaft	Derives de carboxamide, inhibiteurs selectifs d'agents pathogenes
US6867299B2 (en)	2000-02-24	2005-03-15	Hoffmann-La Roche Inc.	Oxamide IMPDH inhibitors
WO2001081340A2 (fr)	2000-04-24	2001-11-01	Bristol-Myers Squibb Company	Heterocycles utiles en tant qu'inhibiteurs de l'enzyme impdh
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20030105073A1 (en) *	2001-10-23	2003-06-05	Haughan Alan Findlay	Quinolone derivatives
DE10163239A1 (de) *	2001-12-21	2003-07-10	Aventis Pharma Gmbh	Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
TW200301698A (en)	2001-12-21	2003-07-16	Bristol Myers Squibb Co	Acridone inhibitors of IMPDH enzyme
GB0208223D0 (en) *	2002-04-10	2002-05-22	Celltech R&D Ltd	Chemical compounds
AU2003261354A1 (en) *	2002-08-02	2004-02-23	The Regents Of The University Of California	New uses for inhibitors of inosine monophosphate dehydrogenase
CA2511521C (fr)	2002-12-30	2012-02-07	Angiotech International Ag	Liberation de medicaments a partir d'une composition polymere a gelification rapide
DE10304294A1 (de) *	2003-02-04	2004-08-12	Aventis Pharma Deutschland Gmbh	N-Substituierte(Benzoimidazol-2-yl)-phenyl, Verfahren zu ihrer Herstellung , ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20050054705A1 (en) *	2003-02-04	2005-03-10	Aventis Pharma Deutschland Gmbh	N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
CN1852920B (zh)	2003-07-18	2010-12-15	沃泰克斯药物股份有限公司	丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
TWI359147B (en)	2003-09-05	2012-03-01	Vertex Pharma	Inhibitors of serine proteases, particularly hcv n
MXPA06004006A (es)	2003-10-10	2006-06-28	Vertex Pharma	Inhibidores de serina proteasas, especialmente de ns3-ns4a proteasa del virus de la hepatitis c.
EP1944042A1 (fr)	2003-10-27	2008-07-16	Vertex Pharmceuticals Incorporated	Combinaisons pour le traitement HCV
JP4890254B2 (ja)	2003-10-27	2012-03-07	バーテックスファーマシューティカルズインコーポレイテッド	Ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ耐性突然変異体
GB0401334D0 (en) *	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US7262223B2 (en)	2004-01-23	2007-08-28	Neurochem (International) Limited	Amidine derivatives for treating amyloidosis
JP2008505849A (ja)	2004-02-04	2008-02-28	バーテックス　ファーマシューティカルズ　インコーポレイテッド	セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
MX2007003812A (es)	2004-10-01	2007-05-24	Vertex Pharma	Inhibicion de proteasa ns3-ns4a del virus de la hepatitis c (vhc).
MY141025A (en)	2004-10-29	2010-02-25	Vertex Pharma	Dose forms
WO2006136580A2 (fr) *	2005-06-21	2006-12-28	Neurosearch A/S	Nouveaux derives de 2-(phenylamino)benzimidazole et utilisation de ceux-ci en tant que modulateurs de canaux de potassium actives par le calcium a faible conductance
JO2768B1 (en)	2005-07-29	2014-03-15	تيبوتيك فارماسيوتيكالز ليمتد	Large cyclic inhibitors of hepatitis C virus
DE602006019883D1 (de)	2005-07-29	2011-03-10	Medivir Ab	Makrocyclische inhibitoren des hepatitis-c-virus
ES2389964T3 (es)	2005-07-29	2012-11-05	Janssen R&D Ireland	Inhibidores macrocíclicos del virus de la hepatitis C
JP5171624B2 (ja)	2005-07-29	2013-03-27	テイボテク・フアーマシユーチカルズ	Ｃ型肝炎ウイルスの大環状阻害剤
PE20070210A1 (es)	2005-07-29	2007-04-16	Tibotec Pharm Ltd	Compuestos macrociclicos como inhibidores del virus de hepatitis c
DK1912997T3 (da)	2005-07-29	2012-01-02	Tibotec Pharm Ltd	Makrocycliske inhibitorer af hepatitis C virus
US8183277B2 (en)	2005-07-29	2012-05-22	Tibotec Pharmaceuticals Ltd.	Macrocylic inhibitors of hepatitis C virus
AU2006274862B2 (en)	2005-07-29	2012-03-22	Medivir Ab	Macrocyclic inhibitors of hepatitis C virus
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
US20070105781A1 (en) *	2005-08-02	2007-05-10	Steve Lyons	Inhibitors of serine proteases
US7964624B1 (en)	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
AR055395A1 (es) *	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
PE20070427A1 (es) *	2005-08-30	2007-04-21	Novartis Ag	Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US7705138B2 (en)	2005-11-11	2010-04-27	Vertex Pharmaceuticals Incorporated	Hepatitis C virus variants
CA2629343A1 (fr)	2005-11-11	2007-05-24	Vertex Pharmaceuticals, Inc.	Variantes du virus de l'hepatite c
AU2007217355B2 (en)	2006-02-27	2012-06-21	Vertex Pharmaceuticals Incorporated	Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
EP2194039A1 (fr)	2006-03-16	2010-06-09	Vertex Pharmceuticals Incorporated	Procédé de préparation de composés optiquement actifs
WO2007133865A2 (fr)	2006-04-11	2007-11-22	Novartis Ag	Composés organiques et leurs utilisations
DE102006021878A1 (de) *	2006-05-11	2007-11-15	Sanofi-Aventis	Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2665438C (fr)	2006-10-04	2014-12-02	Tibotec Pharmaceuticals Ltd.	Carboxamide 4-[(4-pyridyl)amino]-pyrimidines utiles comme inhibiteurs de hcv
CN101535294B (zh)	2006-11-17	2014-09-24	泰博特克药品有限公司	丙型肝炎病毒的大环化合物抑制剂
CA2679312A1 (fr) *	2007-02-27	2008-09-04	Vertex Pharmaceuticals Incorporated	Co-cristaux et compositions pharmaceutiques comprenant ceux-ci
CN101903392A (zh) *	2007-02-27	2010-12-01	弗特克斯药品有限公司	丝氨酸蛋白酶的抑制剂
EP2494991A1 (fr)	2007-05-04	2012-09-05	Vertex Pharmaceuticals Incorporated	Polythérapie pour le traitement de l'infection par VHC
WO2009032198A1 (fr) *	2007-08-30	2009-03-12	Vertex Pharmaceuticals Incorporated	Co-cristaux et compositions pharmaceutiques les comportant
AU2008339917B2 (en)	2007-12-24	2013-02-07	Tibotec Pharmaceuticals	Macrocyclic indoles as hepatitis C virus inhibitors
TWI454476B (zh)	2008-07-08	2014-10-01	Tibotec Pharm Ltd	用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
PT2331554E (pt)	2008-08-14	2013-05-21	Janssen R & D Ireland	Derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c
WO2010048514A1 (fr)	2008-10-23	2010-04-29	Albany Molecular Research, Inc.	Synthèse de composés de 2-amino-benzoxazole
CN104163816A (zh)	2008-12-03	2014-11-26	普雷西迪奥制药公司	Hcv ns5a的抑制剂
WO2010065681A1 (fr)	2008-12-03	2010-06-10	Presidio Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hépatite c de type ns5a
EP2396028A2 (fr)	2009-02-12	2011-12-21	Vertex Pharmceuticals Incorporated	Polythérapie contre le hcv comprenant de l'interféron pégylé, de la ribavirine et de la telaprevir
KR20110131312A (ko)	2009-03-27	2011-12-06	프레시디오 파마슈티칼스, 인코포레이티드	융합된 고리 ｃ형 간염 억제제
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
EP2459211A1 (fr)	2009-07-31	2012-06-06	Medtronic, Inc.	Administration continue par voie sous-cutanée d'interféron- à des patients infectés par le virus de l'hépatite c
UA108211C2 (uk)	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
WO2011094489A1 (fr)	2010-01-29	2011-08-04	Vertex Pharmaceuticals Incorporated	Thérapies pour traiter une infection par le virus de l'hépatite c
WO2011112516A1 (fr)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Traitement et prévention de l'infection par le virus de l'hépatite c en utilisant des oligonucléotides antisens de la kinase c-raf
CA2800509A1 (fr)	2010-05-24	2011-12-01	Presidio Pharmaceuticals, Inc.	Inhibiteurs de ns5a du vhc
NZ604040A (en)	2010-06-03	2015-02-27	Pharmacyclics Inc	The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2011156545A1 (fr)	2010-06-09	2011-12-15	Vertex Pharmaceuticals Incorporated	Modèle dynamique viral pour une polythérapie contre le vhc
BR112012032889A2 (pt)	2010-06-24	2015-09-15	Janssen R & D Ireland	preparação do ácido 13-ciclo-hexil-3-metóxi-6-[metil-(2-{2-[metil-(sulfamoil)-amino]-etóxi}-etil)-carbamoil]-7h-indol-[2,1-a]-[2]-benzazepina-10-carboxílico
AR082215A1 (es)	2010-07-14	2012-11-21	Vertex Pharma	Composicion farmaceutica agradable al paladar
AR082619A1 (es)	2010-08-13	2012-12-19	Hoffmann La Roche	Inhibidores del virus de la hepatitis c
WO2012109646A1 (fr)	2011-02-11	2012-08-16	Vertex Pharmaceuticals Incorporated	Traitement du vhc chez des patients infectés par le vih
WO2012116370A1 (fr)	2011-02-25	2012-08-30	Medtronic, Inc.	Procédés et systèmes utilisant des profils pharmacocinétiques et pharmacodynamiques dans régimes thérapeutiques d'interféron-alpha
WO2012123298A1 (fr)	2011-03-11	2012-09-20	F. Hoffmann-La Roche Ag	Composés antiviraux
BR112013032188A2 (pt)	2011-06-23	2016-12-20	Digna Biotech Sl	composição, produto e método para tratar pacientes com hepatite c crônica
WO2012175581A1 (fr)	2011-06-24	2012-12-27	F. Hoffmann-La Roche Ag	Composés antiviraux
EP2766365A1 (fr)	2011-10-10	2014-08-20	F.Hoffmann-La Roche Ag	Composés antiviraux
RU2014127848A (ru)	2011-12-16	2016-02-10	Ф. Хоффманн-Ля Рош Аг	Ингибиторы hcv ns5a
US9108999B2 (en)	2011-12-20	2015-08-18	Riboscience Llc	2′, 4′-difluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
PL2794628T3 (pl)	2011-12-20	2017-09-29	Riboscience Llc	4'-azydo-3'-fluoro podstawione pochodne nukleozydów jako inhibitory replikacji RNA HCV
WO2013098313A1 (fr)	2011-12-28	2013-07-04	Janssen R&D Ireland	Dérivés hétérobicycliques en tant qu'inhibiteurs de vhc
WO2013116339A1 (fr)	2012-01-31	2013-08-08	Vertex Pharmaceuticals Incorporated	Formulations très puissantes de vx-950
WO2013124335A1 (fr)	2012-02-24	2013-08-29	F. Hoffmann-La Roche Ag	Composés antiviraux
CN103304555B (zh) *	2012-03-08	2016-03-30	中国医学科学院医药生物技术研究所	一组苯-噁唑基衍生物及其制备方法和作为impdh抑制剂的相关应用
KR20150032340A (ko)	2012-07-24	2015-03-25	파마시클릭스, 인코포레이티드	브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
US20140205566A1 (en)	2012-11-30	2014-07-24	Novartis Ag	Cyclic nucleuoside derivatives and uses thereof
SG11201509424VA (en)	2013-05-16	2015-12-30	Riboscience Llc	4'-fluor0-2'-methyl substituted nucleoside derivatives
US20180200280A1 (en)	2013-05-16	2018-07-19	Riboscience Llc	4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
BR112015028765A2 (pt)	2013-05-16	2017-07-25	Riboscience Llc	derivados de nucleosídeo substituído 4'-azido, 3'-desoxi-3'-fluoro
JP6508785B2 (ja)	2013-10-25	2019-05-08	ファーマサイクリックスエルエルシー	ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
JP2017509336A (ja)	2014-03-20	2017-04-06	ファーマサイクリックスエルエルシー	ホスホリパーゼｃガンマ２及び耐性に関連した変異
BR112016030690B1 (pt) *	2014-06-27	2023-11-14	Nogra Pharma Limited	Compostos moduladores do receptor de arila, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
AU2018335411B2 (en)	2017-09-21	2024-06-27	Riboscience Llc	4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
AU2019242628A1 (en)	2018-03-26	2020-09-24	Clear Creek Bio, Inc.	Compositions and methods for inhibiting dihydroorotate dehydrogenase
BR112020025696A2 (pt)	2018-06-19	2021-03-16	Novartis Ag	Derivados de tetra-hidrotienopiridina n-substituída e usos dos mesmos
US12076315B2 (en)	2020-03-20	2024-09-03	Clear Creek Bio, Inc.	Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE603739A (fr) *	1960-05-13
GB1171904A (en) *	1965-10-21	1969-11-26	Unilever Ltd	Anilinobenzimidazoles having Antibacterial Properties
CA985286A (en) *	1971-05-04	1976-03-09	Charles J. Paget (Jr.)	(substituted anilino) benzoxazoles useful in the prophylaxis of mareks disease
DE2928485A1 (de)	1979-07-14	1981-01-29	Bayer Ag	Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US5283257A (en)	1992-07-10	1994-02-01	The Board Of Trustees Of The Leland Stanford Junior University	Method of treating hyperproliferative vascular disease
WO1994012184A1 (fr)	1992-11-24	1994-06-09	Syntex (U.S.A.) Inc.	Utilisation d'acide mycophenolique, de mofetile de mycophenolate ou d'un derive de ceux-ci pour inhiber la stenose
US5444072A (en)	1994-02-18	1995-08-22	Syntex (U.S.A.) Inc.	6-substituted mycophenolic acid and derivatives
US5380879A (en)	1994-02-18	1995-01-10	Syntex (U.S.A.) Inc.	Derivatives of mycophenolic acid
US5807876A (en)	1996-04-23	1998-09-15	Vertex Pharmaceuticals Incorporated	Inhibitors of IMPDH enzyme
US6054472A (en)	1996-04-23	2000-04-25	Vertex Pharmaceuticals, Incorporated	Inhibitors of IMPDH enzyme

1998
- 1998-03-13 AT AT98909165T patent/ATE244717T1/de not_active IP Right Cessation
- 1998-03-13 JP JP53983198A patent/JP4327910B2/ja not_active Expired - Fee Related
- 1998-03-13 DE DE69816280T patent/DE69816280T2/de not_active Expired - Lifetime
- 1998-03-13 AU AU67015/98A patent/AU6701598A/en not_active Abandoned
- 1998-03-13 ES ES98909165T patent/ES2201452T3/es not_active Expired - Lifetime
- 1998-03-13 DK DK98909165T patent/DK0966465T3/da active
- 1998-03-13 PT PT98909165T patent/PT966465E/pt unknown
- 1998-03-13 EP EP98909165A patent/EP0966465B1/fr not_active Expired - Lifetime
- 1998-03-13 CA CA002282398A patent/CA2282398A1/fr not_active Abandoned
- 1998-03-13 WO PCT/US1998/004932 patent/WO1998040381A1/fr not_active Ceased
1999
- 1999-09-14 US US09/395,798 patent/US6518291B1/en not_active Expired - Fee Related
2003
- 2003-03-28 US US10/327,230 patent/US20040048774A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE69816280D1 (de)	2003-08-14
EP0966465B1 (fr)	2003-07-09
JP4327910B2 (ja)	2009-09-09
US6518291B1 (en)	2003-02-11
WO1998040381A1 (fr)	1998-09-17
ES2201452T3 (es)	2004-03-16
EP0966465A1 (fr)	1999-12-29
CA2282398A1 (fr)	1998-09-17
PT966465E (pt)	2003-11-28
AU6701598A (en)	1998-09-29
DE69816280T2 (de)	2004-05-27
JP2001526638A (ja)	2001-12-18
ATE244717T1 (de)	2003-07-15
US20040048774A1 (en)	2004-03-11

Publication	Publication Date	Title
DK0966465T3 (da)	2003-10-20	Inhibitorer af IMPDH-enzymer
AP1498A (en)	2005-11-21	Inhibitors of impdh enzyme.
ATE248835T1 (de)	2003-09-15	Prodrugs von impdh-inhibierenden carbamaten
BG104780A (en)	2001-10-31	Inhibitors of phospholipase enzymes
TR199802136T2 (xx)	2001-06-21	�MPDH enzimi inhibit�rleri olarak �re t�revleri.
ATE226193T1 (de)	2002-11-15	Substituierte zyklische amine als metalloproteaseinhibitoren
ATE310011T1 (de)	2005-12-15	Inhibitoren des interleukin-1-beta konvertierenden enzyms
DE69432035D1 (de)	2003-02-27	Saccharinderivate als proteolytische Enzyminhibitoren
DE60310991D1 (de)	2007-02-15	Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
MXPA02012272A (es)	2003-04-25	Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
DE69232929D1 (de)	2003-04-03	Saccharinderivate als proteolytische Enzyminhibitoren
ATE268766T1 (de)	2004-06-15	Stickstoff enthaltende heterobicyclen als factor xa inhibitoren
ATE232873T1 (de)	2003-03-15	Phosphonsaürederivate als ptp-1b-inhibitoren
ATE516027T1 (de)	2011-07-15	Orazamid orotat zur vorbeugung von leberschäden
BR0014759A (pt)	2002-07-02	Inibidores de metaloprotease beta dissubstituìdos
GEP20033130B (en)	2003-12-25	Inhibitors of IMPDH Enzyme